$ONVO
ORGANOVO HOLDINGS, INC.

2023 Q1 Form 10-Q Financial Statement

#000095017023002327 Filed on February 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022 Q1
Revenue $162.0K $131.0K $1.500M
YoY Change -89.2%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.478M $2.305M $2.265M
YoY Change 9.4% -10.28% 17.91%
% of Gross Profit
Research & Development $5.404M $1.185M $1.102M
YoY Change 390.38% 27.97% 68.24%
% of Gross Profit
Depreciation & Amortization $59.00K $130.0K $46.00K
YoY Change 28.26% 251.35% 119.05%
% of Gross Profit
Operating Expenses $7.941M $3.490M $3.413M
YoY Change 132.67% 276.89% 31.37%
Operating Profit -$3.359M
YoY Change -4.03%
Interest Expense $329.0K $95.00K $2.000K
YoY Change 16350.0% 4650.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $95.00K $0.00
YoY Change
Pretax Income -$7.459M -$3.264M -$1.911M
YoY Change 290.32% -6.69% -26.39%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.459M -$3.264M -$1.911M
YoY Change 290.32% -6.74% -26.39%
Net Earnings / Revenue -4604.32% -2491.6% -127.4%
Basic Earnings Per Share -$0.37
Diluted Earnings Per Share -$0.86 -$0.37 -$219.5K
COMMON SHARES
Basic Shares Outstanding 8.715M 8.713M
Diluted Shares Outstanding 8.714M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.01M $20.75M $28.68M
YoY Change -44.18% -31.45% -23.26%
Cash & Equivalents $15.30M $20.20M $28.68M
Short-Term Investments $706.0K $554.0K
Other Short-Term Assets $889.0K $788.0K $858.0K
YoY Change 3.61% -12.64% -17.02%
Inventory $0.00
Prepaid Expenses $313.0K
Receivables $152.0K $76.00K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $17.05M $21.61M $29.53M
YoY Change -42.27% -30.66% -23.09%
LONG-TERM ASSETS
Property, Plant & Equipment $2.607M $742.0K $662.0K
YoY Change 293.81% -74.6% 73.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $658.0K $920.0K $948.0K
YoY Change -30.59% -8.28% -7.69%
Total Long-Term Assets $3.265M $3.465M $3.763M
YoY Change -13.23% -11.7% 147.73%
TOTAL ASSETS
Total Short-Term Assets $17.05M $21.61M $29.53M
Total Long-Term Assets $3.265M $3.465M $3.763M
Total Assets $20.31M $25.08M $33.30M
YoY Change -38.99% -28.54% -16.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $331.0K $242.0K $415.0K
YoY Change -20.24% -60.0% 47.69%
Accrued Expenses $3.340M $646.0K $489.0K
YoY Change 583.03% -53.89% 11.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.671M $1.376M $1.383M
YoY Change 165.44% -31.41% 91.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.313M $1.414M $1.704M
YoY Change -22.95% -21.27%
Total Long-Term Liabilities $1.313M $1.414M $1.704M
YoY Change -22.95% -21.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.671M $1.376M $1.383M
Total Long-Term Liabilities $1.313M $1.414M $1.704M
Total Liabilities $4.984M $2.790M $3.087M
YoY Change 61.45% -26.62% 328.16%
SHAREHOLDERS EQUITY
Retained Earnings -$325.0M -$317.5M -$307.7M
YoY Change 5.61% 3.83% 3.86%
Common Stock $340.3M $339.8M $337.9M
YoY Change 0.7% 0.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.33M $22.29M $30.21M
YoY Change
Total Liabilities & Shareholders Equity $20.31M $25.08M $33.30M
YoY Change -38.99% -28.54% -16.59%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022 Q1
OPERATING ACTIVITIES
Net Income -$7.459M -$3.264M -$1.911M
YoY Change 290.32% -6.74% -26.39%
Depreciation, Depletion And Amortization $59.00K $130.0K $46.00K
YoY Change 28.26% 251.35% 119.05%
Cash From Operating Activities -$4.733M -$3.044M -$1.541M
YoY Change 207.14% -9.3% -27.07%
INVESTING ACTIVITIES
Capital Expenditures $162.0K $41.00K -$53.00K
YoY Change -405.66% -130.83% -53.91%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.02M $0.00
YoY Change -100.0%
Cash From Investing Activities -$162.0K $9.975M -$53.00K
YoY Change 205.66% -7600.0% -53.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.733M -3.044M -1.541M
Cash From Investing Activities -162.0K 9.975M -53.00K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -4.895M 6.931M -1.594M
YoY Change 207.09% -298.6% -108.6%
FREE CASH FLOW
Cash From Operating Activities -$4.733M -$3.044M -$1.541M
Capital Expenditures $162.0K $41.00K -$53.00K
Free Cash Flow -$4.895M -$3.085M -$1.488M
YoY Change 228.97% -4.28% -25.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Dilutive Securities
DilutiveSecurities
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1100000
onvo Vesting Criteria Probability Of Achievement Percentage
VestingCriteriaProbabilityOfAchievementPercentage
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
0
CY2022Q4 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35996
dei Entity Registrant Name
EntityRegistrantName
Organovo Holdings, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1488943
dei Entity Address Address Line1
EntityAddressAddressLine1
11555 Sorrento Valley Rd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
224-1000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
242000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
ONVO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8714590
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20196000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28675000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
76000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 onvo Equity Securities Current
EquitySecuritiesCurrent
554000
CY2022Q1 onvo Equity Securities Current
EquitySecuritiesCurrent
0
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
788000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
858000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
21614000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
29533000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
742000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
662000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
143000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
143000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1803000
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001497253
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#RoyaltyMember
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2153000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
777000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
805000
CY2022Q4 us-gaap Assets
Assets
25079000
CY2022Q1 us-gaap Assets
Assets
33296000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
415000
CY2022Q4 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-48000
CY2021Q4 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
646000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
488000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
479000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1376000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1383000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1414000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1704000
CY2022Q4 us-gaap Liabilities
Liabilities
2790000
CY2022Q1 us-gaap Liabilities
Liabilities
3087000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8714590
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8714590
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8710627
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8710627
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
9000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339817000
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
337940000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317539000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-307739000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
46
CY2022Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
46
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1000
CY2022Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
1000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
22289000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
30209000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25079000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33296000
CY2022Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
131000
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
208000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1185000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
926000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3436000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2185000
CY2022Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2305000
CY2021Q4 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2574000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6724000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7381000
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
3490000
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
3500000
us-gaap Operating Expenses
OperatingExpenses
10160000
us-gaap Operating Expenses
OperatingExpenses
9566000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3359000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-3500000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9952000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9566000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-123000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37330000
CY2021Q3 onvo Stock Issued During Period Value Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
-45000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-3505000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
34206000
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
143000
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
277000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
95000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
154000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
31000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3264000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3500000
us-gaap Net Income Loss
NetIncomeLoss
-9800000
us-gaap Net Income Loss
NetIncomeLoss
-9537000
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2021Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3261000
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9797000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9537000
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8713617
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8713617
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8705503
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8705503
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8712294
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8712294
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8702959
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8702959
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39196000
CY2021Q2 onvo Stock Issued During Period Value Public Offering
StockIssuedDuringPeriodValuePublicOffering
251000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
415000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-2532000
CY2021Q4 onvo Stock Issued During Period Value Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
-1000
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
588000
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-3500000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
31293000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
30209000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
205000
CY2022Q2 onvo Stock Issued During Period Value Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
0
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
660000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-3215000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
27654000
CY2022Q3 onvo Stock Issued During Period Value Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodValueUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
0
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
673000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3321000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
25006000
CY2022Q4 onvo Stock Issued During Period Shares Under Employee And Director Stock Option Rsu And Purchase Plans
StockIssuedDuringPeriodSharesUnderEmployeeAndDirectorStockOptionRSUAndPurchasePlans
0
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
544000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-3264000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
3000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
22289000
us-gaap Profit Loss
ProfitLoss
-9800000
us-gaap Profit Loss
ProfitLoss
-9537000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-123000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
onvo Accretion On Investments
AccretionOnInvestments
104000
onvo Accretion On Investments
AccretionOnInvestments
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
234000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
96000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1877000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1429000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
76000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-288000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-173000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
324000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
157000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
486000
onvo Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
69000
onvo Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet
2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7675000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6912000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
234000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
356000
onvo Payments To Acquire Investment
PaymentsToAcquireInvestment
9893000
onvo Payments To Acquire Investment
PaymentsToAcquireInvestment
0
onvo Proceeds From Maturities Prepayments And Calls Of Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfInvestments
10000000
onvo Proceeds From Maturities Prepayments And Calls Of Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfInvestments
0
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
1061000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
0
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
384000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-804000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-356000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
251000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8479000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
46000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0120
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0321
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0119
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7063000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28818000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37475000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20339000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30412000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20196000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30269000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
143000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
143000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20339000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30412000
us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
us-gaap Income Taxes Paid
IncomeTaxesPaid
2000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Nature of Operations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organovo Holdings, Inc. (“Organovo Holdings,” “Organovo,” and the “Company”) is an early-stage biotechnology company that focuses on building high fidelity, 3D tissues that recapitulate key aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. The Company is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (“UC”) and Crohn’s disease (“CD”). Recently, the Company announced that it has successfully advanced its first inflammatory bowel disease (“IBD”) model to the next step of target discovery and validation for CD. The Company intends to add additional tissues/diseases/targets to its portfolio over time. In line with these plans, the Company is building upon both its external and in house scientific expertise, which will be essential to its drug development effort.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Organovo’s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs across multiple therapeutic areas.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s NovoGen Bioprinters</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. The Company believes that the use of its bioprinting platform as well as complementary 3D technologies will allow it to develop an understanding of disease biology that leads to validated novel drug targets and therapeutics to those targets to treat disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The majority of the Company’s current focus is in IBD, including CD and UC. The Company is creating high fidelity disease models, leveraging its prior work including the work found in its peer-reviewed publication on bioprinted intestinal tissues (</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Madden et al. Bioprinted 3D Primary Human Intestinal Tissues Model Aspects of Native Physiology and ADME/Tox Functions. iScience. 2018 Apr 27;2:156-167. doi: 10.1016/j.isci.2018.03.015.) The Company’s current understanding of intestinal tissue models and IBD disease models leads it to believe that it can create models that provide greater insight into the biology of these diseases than are generally currently available. Using these disease models, the Company has identified and validated novel therapeutic targets and is actively focused on developing novel small molecule, antibody, or other therapeutic drug candidates to treat the disease, and advance these novel drug candidates towards an Investigational New Drug (“IND”) filing and potential future clinical trials.</span><span style="color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,33,33,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expects to broaden its work into additional therapeutic areas over time and is currently exploring specific tissues for development. In the Company’s work to identify the areas of interest, it evaluates areas that might be better served with 3D disease models than currently available models as well as the potential commercial opportunity.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Except where specifically noted or the context otherwise requires, references to “Organovo Holdings”, “the Company”, and “Organovo” in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc., and Opal Merger Sub, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global health concerns relating to the COVID-19 pandemic continue to weigh on the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the rise of vaccine-resistant variants, the duration of the outbreak, and any </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">travel bans and restrictions or other limitations that may be imposed in the future</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In particular, the continued coronavirus pandemic could adversely impact various aspects of the Company’s operations, including among others, the ability to raise additional capital, the timing and ability to pursue the Company’s strategy, given the impact the pandemic may have on the manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners, and the ability to advance its research and development activities and pursue development of its pipeline products, each of which could have an adverse impact on the Company’s business and financial results. Company employees and consultants have returned to working at the office and lab when necessary. The Company has developed guidelines and protocols to handle exposures and infections to keep disruptions to operations to a minimum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20200000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7700000
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2022Q4 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021Q4 us-gaap Dilutive Securities
DilutiveSecurities
0
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M8D
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in revenue recognition and the valuation of stock-based compensation expense. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its significant accounting estimates.</span></p>
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.23
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.20
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20200000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
1100000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
400000
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
600000
us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
100000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
544000
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
588000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1877000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1429000
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2900000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9593
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9542
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9543
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9596
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0397
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.23
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 onvo Combination Of Securities Authorized For Offer And Sale
CombinationOfSecuritiesAuthorizedForOfferAndSale
150000000.0
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
460000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2154000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
252000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1902000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1203671
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.36
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
71650
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
209474
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
6092
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.38
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1407053
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.65
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
487477
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.28
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y2M1D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M1D
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2712181
onvo Monthly Rent Payments
MonthlyRentPayments
4000
CY2020Q4 onvo Number Of Lease Agreement
NumberOfLeaseAgreement
2
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2300000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
488000
CY2022Q4 onvo Operating Lease Right Of Use Asset Non Current
OperatingLeaseRightOfUseAssetNonCurrent
1803000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1803000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
488000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1414000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1902000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y29D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.06
CY2022Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
0
us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2021Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
0
us-gaap Operating Lease Cost
OperatingLeaseCost
18000
CY2022Q4 us-gaap Variable Lease Cost
VariableLeaseCost
34000
us-gaap Variable Lease Cost
VariableLeaseCost
110000
CY2021Q4 us-gaap Variable Lease Cost
VariableLeaseCost
9000
us-gaap Variable Lease Cost
VariableLeaseCost
27000
CY2022Q4 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2021Q4 us-gaap Short Term Lease Cost
ShortTermLeaseCost
39000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
117000
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
114000
us-gaap Operating Lease Expense
OperatingLeaseExpense
373000
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
43000
us-gaap Operating Lease Expense
OperatingLeaseExpense
43000
CY2022Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
59000
us-gaap Operating Lease Payments
OperatingLeasePayments
304000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
126000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
508000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
522000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
538000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1414000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
onvo-20221231_cal.xml Edgar Link unprocessable
onvo-20221231_def.xml Edgar Link unprocessable
0000950170-23-002327-index-headers.html Edgar Link pending
0000950170-23-002327-index.html Edgar Link pending
0000950170-23-002327.txt Edgar Link pending
0000950170-23-002327-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
onvo-20221231.htm Edgar Link pending
onvo-20221231.xsd Edgar Link pending
onvo-ex31_1.htm Edgar Link pending
onvo-ex31_2.htm Edgar Link pending
onvo-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
onvo-20221231_lab.xml Edgar Link unprocessable
onvo-20221231_pre.xml Edgar Link unprocessable
onvo-20221231_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending